» Articles » PMID: 10807776

In Vitro Differentiation of Endothelial Cells from AC133-positive Progenitor Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 May 16
PMID 10807776
Citations 251
Authors
Affiliations
Soon will be listed here.
Abstract

Recent findings support the hypothesis that the CD34(+)-cell population in bone marrow and peripheral blood contains hematopoietic and endothelial progenitor and stem cells. In this study, we report that human AC133(+) cells from granulocyte colony-stimulating factor-mobilized peripheral blood have the capacity to differentiate into endothelial cells (ECs). When cultured in the presence of vascular endothelial growth factor (VEGF) and the novel cytokine stem cell growth factor (SCGF), AC133(+) progenitors generate both adherent and proliferating nonadherent cells. Phenotypic analysis of the cells within the adherent population reveals that the majority display endothelial features, including the expression of KDR, Tie-2, Ulex europaeus agglutinin-1, and von Willebrand factor. Electron microscopic studies of these cells show structures compatible with Weibel-Palade bodies that are found exclusively in vascular endothelium. AC133-derived nonadherent cells give rise to both hematopoietic and endothelial colonies in semisolid medium. On transfer to fresh liquid culture with VEGF and SCGF, nonadherent cells again produce an adherent and a nonadherent population. In mice with severe combined immunodeficiency, AC133-derived cells form new blood vessels in vivo when injected subcutaneously together with A549 lung cancer cells. These data indicate that the AC133(+)-cell population consists of progenitor and stem cells not only with hematopoietic potential but also with the capacity to differentiate into ECs. Whether these hematopoietic and endothelial progenitors develop from a common precursor, the hemangioblast will be studied at the single-cell level.

Citing Articles

100% oxygen mobilizes stem cells and up-regulates MIF and APRIL in humans: a new point on the hormetic dose curve.

MacLaughlin K, Barton G, MacLaughlin J, Lamers J, Marcou M, OBrien M Front Cell Dev Biol. 2025; 12:1377203.

PMID: 39974348 PMC: 11836035. DOI: 10.3389/fcell.2024.1377203.


Endothelial Progenitor Cells: A Review of Molecular Mechanisms in the Pathogenesis and Endovascular Treatment of Intracranial Aneurysms.

Ramirez-Velandia F, Mensah E, Salih M, Wadhwa A, Young M, Muram S Neuromolecular Med. 2024; 26(1):25.

PMID: 38886284 DOI: 10.1007/s12017-024-08791-4.


Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.

Gold D, Sandesara P, Kindya B, Gold M, Jain V, Vatsa N Int J Cardiol. 2024; 407:132104.

PMID: 38677332 PMC: 11559591. DOI: 10.1016/j.ijcard.2024.132104.


Role of Bushen Huoxue Formula and transplanted endothelial progenitor cells play in promoting endplate microcirculation and attenuating intervertebral disc degeneration.

Xie Y, Zhang J, Yang S, Zhai W, Zhao H, Shen Z Heliyon. 2024; 10(6):e28095.

PMID: 38545187 PMC: 10966705. DOI: 10.1016/j.heliyon.2024.e28095.


Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease.

Pleskac P, Fargeas C, Veselska R, Corbeil D, Skoda J Cell Mol Biol Lett. 2024; 29(1):41.

PMID: 38532366 PMC: 10967083. DOI: 10.1186/s11658-024-00554-0.